Background: Genome-wide association studies have identified multiple loci associated with 69 stroke. However, the specific stroke subtypes affected, and whether loci influence both 70 ischaemic and haemorrhagic stroke, remains unknown. For loci associated with stroke, we 71 aimed to infer the combination of stroke subtypes likely to be affected, and in doing so assess 72 the extent to which such loci have homogeneous effects across stroke subtypes. 73
Introduction 92
The burden of stroke on global healthcare and society is substantial; it is consistently one of 93 the leading causes of death and disability worldwide, [1] and a major cause of cognitive 94 impairment and dementia. However, there exist significant gaps in our understanding of the 95 pathological processes that underlie the disease. In recent years genome-wide association 96 studies (GWAS) have made considerable advances in identifying genetic components 97 underlying complex traits, in many cases identifying novel disease pathways and 98 treatments.
[2] 99 100 Characterizing the genetic component to stroke has been challenging, in part due to clinical 101 heterogeneity, with at least three distinct major pathological processes (cardioembolism, large 102 artery atherosclerosis, small vessel disease) underlying the majority of ischaemic strokes; and 103 two processes underlying the majority of intracerebral haemorrhagic stroke (small vessel 104 disease and cerebral amyloid angiopathy). [3, 4] However, recent GWAS have made 105 considerable advances; 32 independent genome-wide significant loci were identified in the 106 MEGASTROKE project.
[5] The majority of these loci were identified as being associated with 107 inclusive 'all stroke' or 'ischaemic stroke' categories, rather than specific stroke subtypes. This 108 is in part due to study design, with much larger samples for these broader categories and only 109 a fraction of stroke cases having detailed phenotyping. Indeed, this finding is in contrast to 110 earlier studies that identified loci such as HDAC9, PITX2 as being associated with specific 111 subtypes. [6, 7] In order to interpret genetic risk associations in the context of biological 112 mechanisms, a pertinent question is whether the newly identified stroke-associated loci truly 113 confer risk across all stroke subtypes, or whether isolated or combinations of subtypes are 114 affected. At least one of the novel variants (on chromosome 1q22) shows association with 115 both ischaemic and haemorrhagic stroke, which might point to some shared mechanisms 116 underlying these clinically distinct entities, which have thus far been separated in genetic 117 studies. 118 6 119 Conventional approaches to GWAS, which employ within study analysis and subsequent 120 meta-analysis across groups, do not enable detailed model comparison across different 121 subgroups. In this analysis, we used multinomial logistic regression on well-characterized 122 subjects with individual-level data to investigate the association of all identified genetic GWAS 123 loci to date with all stroke subtypes (cardioembolic (CES), large artery stroke (LAS), small 124 vessel stroke (SVS) and intracerebral haemorrhage (ICH)), determining the most likely 125 combination of stroke subtypes affected at each locus. We performed our analysis using two 126 established subtyping approaches: the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 127
[8] and Causative Classification of Stroke (CCS) system,[9] to provide a comprehensive 128 account of these loci across available classification systems. Our overall aim was to evaluate 129 genetic loci identified in previous studies using stroke datasets with well-defined phenotyping 130 to determine if subtype specificity or cross-subtype associations could be identified. 131
132
Methods 133
Cohort Characteristics 134
The data used in this analysis were derived from several sources: the NINDS-SIGN Stroke 135 For each locus associated with stroke or stroke subtypes at genome-wide significance in 167 MEGASTROKE, [5] we identified all SNPs in LD (r 2 >0.2) with the lead reported SNP based on 168 the five European populations from 1000 Genomes.
[17] These SNPs were then extracted from 169 8 the merged dataset for analysis. We did not analyse two regions from MEGASTROKE: RGS7 170 and TMFSF1-TMFSF4, as the previously associated variants in these regions were low 171 frequency variants that were filtered out in our analysis. We additionally considered the 172 COL4A2 locus as it been robustly associated with stroke phenotypes in other large-scale 173 studies.
[18] 174 175
Multinomial Logistic Regression 176
We used a Bayesian multinomial logistic regression approach, implemented in Trinculo, [19] 177 to evaluate the association of SNPs at each locus. Multinomial logistic regression is a natural 178 extension of logistic regression that enables modelling of multiple phenotypic categories 179 simultaneously against a common set of controls. The benefit of this approach, which is 180 leveraged in this analysis, is that it enables comparison of models that include different 181 combinations of phenotypes. In the context of genetic studies, this enables determination of 182 the combination of phenotypes that are mostly likely to be associated with the genetic variant 183 of interest. 184
We used the default prior, which assumes effect sizes are independent with variances of 0.04. 185
All analyses included eight ancestry-informative principal components, and batch covariates 186 for each study. 187
Based on their association at genome-wide significance in previous analyses, we assumed a 188 priori that each region was associated with stroke. However, to avoid overfitting for weakly 189 associated loci in our data, we performed model selection only for loci that had a Bayes Factor 190 of at least 4 in either TOAST or CCS analyses. 191
No prior genome-wide association study of stroke has identified a significant association with 192 strokes of undetermined or cryptogenic cause. Given that this study was intended to evaluate 193 potential shared mechanisms between subtypes, we excluded strokes of undetermined cause 194 in model fitting. After QC, there were up to 16,664 cases and 32,792 controls remaining for analysis (Table 1) . 211
In the merged dataset, a binomial genome-wide analysis of all cases against controls had a 212 genomic inflation lambda=1.09, while the LDSCORE intercept value was 1.04, [20] suggesting 213 that the majority of inflation was due to polygenicity and that any bias introduced by merging 214 the datasets was minimal. A comparison of odds ratios for analysed loci from MEGASTROKE 215 and the most recent ICH publication with those from our analysis showed high consistency 216 Our main findings are twofold. First, for the vast majority of loci studied, multiple but never all 264 stroke subtypes were affected at the locus. Only one locus (12q24) was assumed to influence 265 all ischaemic stroke subtypes. This indicates that although these loci were identified in 266 analyses of inclusive stroke phenotypes, in the main their effects are specific to particular 267 combinations of stroke subtypes. The mean number of subtypes affected was 1.88 for TOAST 268 and 1.69 for CCS classification systems. Notable exceptions were the PITX2 and ZFHX3 loci, 269 which were associated with cardioembolic stroke most likely through atrial fibrillation, and 270 HDAC9 which is associated with large vessel stroke. Under TOAST, the FOXF2 locus was 12 associated solely with SVS. However, under CCS, LAS was also implicated. For CCS, the 272 9p21 locus was predicted to influence only LAS. However, under TOAST, SVS was also 273 implicated. Our analyses suggest that ANK2 confers risk of stroke predominantly through its 274 influence on ICH. We were unable to identify any loci for which the most likely model included suggesting that higher levels of ETA are pro-atherogenic: consistent with the observation that 297 13 higher ETA levels are observed in atherosclerotic plaques.
[28] This is also consistent with the 298 C allele of rs17612742 in our study leading to increased risk of ischaemic stroke through 299 elevated ETA levels. Indeed, in GWA studies of intracranial aneurysm the susceptibility variant 300 (in LD with the T allele of rs17612742 in our study) was shown to result in higher transcription 301 factor binding affinity, likely resulting in repression of the transcriptional activity of EDNRA. 302
[23] The reason why lower levels of ETA might promote intracranial aneurysm and 303 intracerebral haemorrhage is not immediately obvious, but several mechanisms are possible. 304
Levels of ET-1 have been linked to vascular remodelling, an important process underlying ICH 305 and IA; [29, 30] subtle changes in this process induced by altered availability of ETA is one 306 such mechanism. Deep ICH and ischaemic SVS arise due to the same arteriopathy that arises 307 in the deep perforating arteries of the brain. The EDNRA variant in this study points to a 308 mechanism that influences whether the resulting pathology is ischaemic or haemorrhagic, and 309 as such warrants further detailed investigation. 310 311 Some loci were notably more significant when phenotyped using CCS; SH3XPD2A, MMP12, 312 TSPAN2, FOXF2, EDNRA, which might point to CCS having greater accuracy and therefore 313 utility in stroke GWA studies. However, the opposite was also true for others: 16q24, HDAC9. 314
We note that some differences may be due to the fact that not all individuals were subtyped 315 under both CCS and TOAST; the TOAST cohort was a least 20% larger. A detailed discussion 316 of the relative merits of TOAST and CCS is beyond the scope of this article, but our results 317 highlight that the importance of collecting individual phenotypic qualities that make up the 318 etiologic subtypes in genetic studies of stroke so that associated loci can be more 319 systematically examined. 320
321
Our study has several strengths. The dataset was a large stroke population including 322 intracerebral haemorrhage and ischaemic stroke cases, the majority of which were subtyped 323 14 under both TOAST and CCS. We had full access to genotype-level data enabling us full control 324 over all analyses. Similarly there are limitations. We present results for the most likely 325 combination of stroke phenotypes affected at each locus: the 'best-fitting' model. We had 326 limited statistical power to determine with statistical certainty that this was the correct model; 327 significantly larger samples would be required to achieve this. Due to the challenges of 328 performing these analyses across different ancestry populations, we performed analyses in 329 European populations only. The results can therefore not be generalized to all populations. In 330 all analyses we assume there is a single causal variant at the locus, which may not be true in 331 all cases. Our analyses are based on use of a default prior, which has been used in many 332 genetic studies. An alternative is to derive an empirical prior from associated genetic loci. As 333 more loci are identified as being associated with stroke, this will become a more realistic 334 possibility and should be explored in future analyses. 335 336
Conclusions 337
Our findings suggest that although large scale genome-wide studies of broad 'all stroke' or 'all 338 ischaemic stroke' phenotypes are able to identify multiple associations, it should not be 339 assumed that such associations confer risk equally across stroke subtypes. Heterogeneity in 340 the influence of genetic variants on different stroke subtypes is the norm, not the exception. 341
Analyses such as the current one provide insights into the etiological stroke subtypes most 342 prominently influenced by genetic variants at these loci -a prerequisite to decide on the most 343 appropriate model systems to choose for further mechanistic studies. Stroke is a complex, 344 Dr. Anderson has consulted for ApoPharma, Inc. 382
